MARKET

ACER

ACER

Acer Therapeutic
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.720
-0.010
-0.37%
Closed 16:00 11/23 EST
OPEN
2.730
PREV CLOSE
2.730
HIGH
2.769
LOW
2.690
VOLUME
67.05K
TURNOVER
--
52 WEEK HIGH
7.25
52 WEEK LOW
1.080
MARKET CAP
33.42M
P/E (TTM)
-1.3124
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Read This Before Selling Acer Therapeutics Inc. (NASDAQ:ACER) Shares
It is not uncommon to see companies perform well in the years after insiders buy shares. On the other hand, we'd be...
Simply Wall St. · 10/01 12:04
LD Micro - 360 Companies Set to Present this Week
ACCESSWIRE · 08/31 22:00
Healthcare - Top 5 Gainers / Losers
Gainers: Aduro Biotech (ADRO) +20%. Otonomy (OTIC) +14%. BeyondSpring (BYSI) +13%. Verrica Pharmaceuticals (VRCA) +13%. STRATA Skin Sciences (SSKN) +11%.Losers: Poseida Therapeutics (PSTX) -30%. Acer Therapeutics (ACER) -20%. Biofrontera (BFRA) -15%. Unity Biotechnology
Seekingalpha · 08/18 15:02
Acer Therapeutics EPS misses by $0.18
Acer Therapeutics (ACER): Q2 GAAP EPS of -$0.56 misses by $0.18.Cash and cash equivalents of $5.9M.Press Release
Seekingalpha · 08/13 20:23
Acer Therapeutics EPS misses by $0.18
Acer Therapeutics (ACER): Q2 GAAP EPS of -$0.56 misses by $0.18.Cash and cash equivalents of $5.9M.Press Release
Seekingalpha · 08/13 20:23
Acer Therapeutics Q2 EPS $(0.56) Up From $(1.09) YoY
Acer Therapeutics (NASDAQ:ACER) reported quarterly losses of $(0.56) per share. This is a 48.62 percent increase over losses of $(1.09) per share from the same period last year.
Benzinga · 08/13 20:04
Insider Buys Acer Therapeutics's Shares
Shares of Acer Therapeutics Inc (NASDAQ:ACER) moved higher by 7.5% from the previous closing price. A Form 4 filing filed with the SEC on Tuesday, July 28 showed that President & CEO Schelling Chris bought 142,857 shares at an average price of $3.50. The trans
Benzinga · 07/28 15:09
Acer Therapeutics Entered Securities Purchase Agreement For Sale And Issuance Of 244.998K Shares Of Common Stock
On July 24, 2020, Acer Therapeutics Inc., a Delaware corporation (the “Company”), entered into a securities purchase agreement (the “Purchase Agreement”) for the sale and issuance of an aggregate
Benzinga · 07/27 13:15
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACER. Analyze the recent business situations of Acer Therapeutic through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACER stock price target is 10.00 with a high estimate of 10.00 and a low estimate of 10.00.
EPS
Institutional Holdings
Institutions: 60
Institutional Holdings: 2.33M
% Owned: 18.96%
Shares Outstanding: 12.29M
TypeInstitutionsShares
Increased
4
104.16K
New
13
1.98K
Decreased
12
188.12K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.80%
Pharmaceuticals & Medical Research
-0.36%
Key Executives
Chairman/Independent Director
Stephen Aselage
President/Chief Executive Officer/Director
Christopher Schelling
Chief Financial Officer
Harry Palmin
Vice President - Finance/Controller
Jason Kneeland
Vice President
Stacey Bain
Vice President
Terrie Kellmeyer
Vice President
John Klopp
Vice President
Kristin Mulready
Vice President
Matt Seibt
Other
William Andrews
Director of Marketing
Kim Tharaldsen
Independent Director
Jason Amello
Independent Director
Hubert Birner
Independent Director
John Dunn
Independent Director
Michelle Griffin
Independent Director
Luc Marengere
  • Dividends
  • Splits
  • Insider Activity
No Data
  • All
  • Financials
  • Insiders
More
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ACER
Acer Therapeutics Inc., formerly Opexa Therapeutics, Inc., is a pharmaceutical company. The Company is engaged in acquires, develops and intends to commercialize therapies for patients with serious rare diseases with critical unmet medical need. Its late-stage clinical pipeline includes Edsivo (celiprolol) and ACER-001. The Company is developing Edsivo for the treatment of vascular Ehlers-Danlos Syndrome (vEDS) in the United States. The Company is developing ACER-001, a pharmacologic treatment option for the treatment of Maple Syrup Urine Disease (MSUD). ACER-001 is an immediate-release formulation of sodium phenylbutyrate (NaPB) developed using a microencapsulation process. The Company is also developing ACER-001 for the treatment of Urea Cycle Disorders (UCD).
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Acer Therapeutics Inc stock information, including NASDAQ:ACER real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACER stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACER stock methods without spending real money on the virtual paper trading platform.